J&J’s Erleada Gives Chase To Xtandi For Non-Metastatic Prostate Cancer With Approval In Europe
Executive Summary
Astellas/Pfizer’s Xtandi and Johnson & Johnson’s Erleada are both now approved for non-metastatic castration-resistant prostate cancer in Europe, while Xtandi benefits from physician familiarity, Erleada has shown greater metastasis-free survival.
You may also be interested in...
Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion
Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary endpoint and could provide a boost for Finland's multinational and now pure-play pharma company, Orion, plus Bayer too.
Opportunities In Fertility: Recognizing Gaps In The Market
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be heading to make a dent in this multi-million-dollar market.
The Power Of AI To Map The Patient Journey
Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.